Results 61 to 70 of about 1,298 (98)

Evaluation of Resident Participation on Specimen Margin Status in Patients Undergoing Lumpectomy

The American surgeon
In the practice of breast surgery, positive margins are a troublesome pathologic finding associated with an increased risk of local recurrence and the recommendation of re-excision.
D. Schmidt, Kristina Fraser, Jared Reyes, S. Helmer, Mohamad Halloum, P. Tenofsky   +5 more
semanticscholar   +1 more source

Abstract 6215: Metabolic risk is an important determinant of adipocyte hypertrophy beyond age, BMI and breast density in patients with ductal carcinoma in situ

Cancer Research
Ductal carcinoma in situ (DCIS) is a non-obligate precursor to invasive breast cancer, but distinguishing patients with harmless from potentially hazardous DCIS remains a challenge.
Charlotta Mulder, M. Almekinders, R. Tissier, L. Mulder, P. Kristel, E. Lips, M. Schmidt, J. Wesseling   +7 more
semanticscholar   +1 more source

Abstract P1-07-13: Adipocyte size in relation to clinical factors, mammographic density and quantitative histologic metrics in ductal carcinoma in situ (DCIS)

Clinical Cancer Research
Background: Ductal carcinoma in situ (DCIS) is a non-obligate precursor to invasive breast cancer, but distinguishing patients with harmless from potentially hazardous ductal carcinoma in situ (DCIS) remains a challenge.
Charlotta Mulder, M. Almekinders, R. Tissier, P. Kristel, E. Lips, M. Schmidt, J. Wesseling   +6 more
semanticscholar   +1 more source

Challenges of surgical management of intrahepatic cholangiocarcinoma

Expert Review of Gastroenterology & Hepatology, 2018
Introduction: Intrahepatic cholangiocarcinoma (iCCA) is a rare malignancy arising from biliary tract epithelium within bile ducts proximal to the secondary biliary radicles.
M. Squires, J. Cloyd, M. Dillhoff, C. Schmidt, T. Pawlik   +4 more
semanticscholar   +1 more source

Abstract 3387: A plasma metabolomic signature improves prediction of malignant intraductal papillary mucinous neoplasm

Cancer Research, 2022
Pancreatic cancer is one of the deadliest cancers primarily because most patients are diagnosed at advanced, unresectable stages. To reduce the incidence and mortality of pancreatic cancer, it is crucial to timely identify and optimally treat its ...
J. Fahrmann, H.-Y. Fan, M. Yip-Schneider, Huangbing Wu, Ziyue Liu, J. Wan, Sheng Liu, S. Hanash, C. Schmidt, Jianjun Zhang   +9 more
semanticscholar   +1 more source

Abstract PR008: Overcoming PDAC T cell therapy barriers with CD47-targeted costimulatory fusion proteins

Cancer Research, 2022
T cell therapy is a promising immunotherapy treatment option that uses genetically modified immune cells (T cells) to eliminate tumors. This approach uses the patients’ own immune cells to generate a “living drug” and can avoid the toxic side effects ...
S. Oda, L. Schmidt, Ashley Thelen, Cody M. Jenkins, E. Chiu, Aitong Ruan, P. Greenberg   +6 more
semanticscholar   +1 more source

Abstract P3-05-28: A clinical risk prediction model for subsequent invasive breast cancer after ductal carcinoma in situ

Clinical Cancer Research
Upon the inception of population-based screening programs, the incidence of ductal carcinoma in situ (DCIS) increased 6-fold. DCIS is a non-obligate precursor lesion of invasive breast cancer (IBC), of which the majority does not progress. This implies
Charlotta Mulder, Will Harley, P. Kristel, L. Mulder, S. Cornelissen, Renée Menezes, M. Schaapveld, M. Schmidt, J. Wesseling, E. Lips   +9 more
semanticscholar   +1 more source

Abstract B069: On the development of the Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts biobank

Cancer Research
The Pancreatic Cancer Detection Consortium (PCDC) is an NCI-sponsored initiative to improve detection of early-stage pancreatic ductal adenocarcinoma (PDAC).
J. Olson, Shounak Majumder, Jennifer J. Brooks, Emily J. Kirsch, Bridget H. Schmidt, Bill R. Bamlet, Erin E Carlson, Ann L. Oberg   +7 more
semanticscholar   +1 more source

Abstract P5-08-15: The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review

Poster Session Abstracts, 2020
Purpose The majority of ‘low-risk’ (grade I/II) Ductal Carcinoma In Situ (DCIS) lesions do not progress to invasive breast cancer during a woman’s lifetime.
S. Alaeikhanehshir, E. Engelhardt, F. Duijnhoven, M. Seijen, P. Bhairosing, D. Pinto, D. Collyar, J. Wesseling, E. Lips, M. Schmidt   +9 more
semanticscholar   +1 more source

Abstract A086: FAK inhibition improves CD40 agonist immunotherapy response and reduces MAPK signaling in pancreatic ductal adenocarcinoma

Cancer Research
Immunotherapy efficacy is limited in pancreatic ductal adenocarcinoma (PDA), due in part to the development of resistance mechanisms. Thus, additional agents are required for overcoming resistance and achieving durable therapeutic benefit.
Anna S. Thickens, M. Stone, Yan Li, Heather Coho, John C McVey, Kelly Markowitz, Andrew D. Schmidt, Kathleen Graham, S. Coma, D. Delman, Jonathan A. Pachter, Gregory Lawrence Beatty   +11 more
semanticscholar   +1 more source